Unraveling Lysosomal Storage Disorders: Emerging Biomarkers in Precision Diagnosis, Disease Monitoring, and Therapeutic Innovation
TL;DR
The use of biomarker-guided assessment is rising and has had a considerable impact on the clinical management of LSDs, allowing earlier diagnosis and more accurate therapy monitoring, however, several practical restrictions continue to influence their routine application.
Abstract
Lysosomal storage diseases (LSDs) are a set of inherited metabolic illnesses heterogeneous in nature and characterized by defective lysosomal activity due to deficits of particular enzymes, transport proteins or activator molecules. These abnormalities impair the normal breakdown of cellular substrates, with gradual buildup in tissues and eventual multisystem involvement. The clinical appearance is typically rather variable from one patient to another, even within the same illness, and this frequently complicates early detection and delays final diagnosis. Biomarkers have become useful tools to increase diagnostic confidence and monitor disease severity and therapeutic response in LSDs, as precision medicine continues to develop. We conducted a narrative evaluation of the current literature using the databases PubMed, Scopus, and Web of Science. A critical review of published literature on biochemical, molecular, and omics-based biomarkers in LSDs was performed. The data in the review were based on enzyme activity assay, substrate-derived biomarker, secondary metabolic marker, molecular genetic testing, and sophisticated proteomic and metabolomic methods. We considered clinically validated biomarkers, such as glucosylsphingosine (lyso-Gb1) in Gaucher disease and globotriaosylsphingosine (lyso-Gb3) in Fabry disease, due to their expanding diagnostic and prognostic value. According to present evidence, the biomarkers employed in LSDs can be generally divided into four main categories. Enzyme-based assays are still the mainstay of first illness confirmation. Accumulated substrate indicators provide information on metabolic burden and treatment response. Secondary biochemical markers mirror downstream pathological changes associated with illness progression. Genetic and omics-derived biomarkers facilitate disease prediction, patient classification, and individual clinical assessment. The introduction of multiplex analytical platforms and integrated biomarker panels has enhanced diagnostic sensitivity and enabled an earlier diagnosis of disease in various subtypes of LSD. The use of biomarker-guided assessment is rising and has had a considerable impact on the clinical management of LSDs, allowing earlier diagnosis and more accurate therapy monitoring. However, several practical restrictions continue to influence their routine application. Differing analytical procedures, low uniformity amongst diagnostic laboratories, high testing costs, and unequal access to specialized technologies continue to be key issues, in particular in the developing healthcare setting. In addition, the clinical interpretation of some of the developing biomarkers is currently awaiting validation by bigger longitudinal research. The combination of validated biomarkers and emerging omics technologies is slowly changing the diagnostic and treatment landscape of lysosomal storage disorders. Biomarker-guided techniques not only increase the accuracy of diagnosis but also allow for individualized treatment and long-term illness monitoring. Continued translational research and wider clinical validation are predicted to strengthen future roles for biomarkers in the precision management of LSDs.